Histidine‐rich glycoprotein ameliorates endothelial barrier dysfunction through regulation of NF‐κB and MAPK signal pathway
-
- Shangze Gao
- Department of Pharmacology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan
-
- Hidenori Wake
- Department of Pharmacology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan
-
- Yuan Gao
- Department of Pharmacology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan
-
- Dengli Wang
- Department of Pharmacology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan
-
- Shuji Mori
- Department of Pharmacology, School of Pharmacy Shujitsu University Okayama Japan
-
- Keyue Liu
- Department of Pharmacology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan
-
- Kiyoshi Teshigawara
- Department of Pharmacology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan
-
- Hideo Takahashi
- Department of Pharmacology, Faculty of Medicine Kindai University Osakasayama Japan
-
- Masahiro Nishibori
- Department of Pharmacology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan
抄録
<jats:sec><jats:title>Background and Purpose</jats:title><jats:p>Microvascular barrier breakdown is a hallmark of sepsis that is associated with sepsis‐induced multiorgan failure. Histidine‐rich glycoprotein (HRG) is a 75‐kDa plasma protein that was demonstrated to improve the survival of septic mice through regulation of cell shape, spontaneous ROS production in neutrophils, and adhesion of neutrophils to vascular endothelial cells. We investigated HRG's role in the LPS/TNF‐α‐induced barrier dysfunction of endothelial cells in vitro and in vivo and the possible mechanism, to clarify the definitive roles of HRG in sepsis.</jats:p></jats:sec><jats:sec><jats:title>Experimental Approach</jats:title><jats:p>EA.hy 926 endothelial cells were pretreated with HRG or human serum albumin before stimulation with LPS/TNF‐α. A variety of biochemical assays were applied to explore the underlying molecular mechanisms on how HRG protected the barrier function of vascular endothelium.</jats:p></jats:sec><jats:sec><jats:title>Key Results</jats:title><jats:p>Immunostaining results showed that HRG maintains the endothelial monolayer integrity by inhibiting cytoskeleton reorganization, losses of VE‐cadherin and β‐catenin, focal adhesion kinase degradation, and cell detachment induced by LPS/TNF‐α. HRG also inhibited the cytokine secretion from endothelial cells induced by LPS/TNF‐α, which was associated with reduced NF‐κB activation. Moreover, HRG effectively prevented the LPS/TNF‐α‐induced increase in capillary permeability in vitro and in vivo. Finally, Western blot results demonstrated that HRG prevented the phosphorylation of MAPK family and RhoA activation, which are involved mainly in the regulation of cytoskeleton reorganization and barrier permeability.</jats:p></jats:sec><jats:sec><jats:title>Conclusions and Implications</jats:title><jats:p>Taken together, our results demonstrate that HRG has protective effects on vascular barrier function in vitro and in vivo, which may be due to the inhibition of MAPK family and Rho activation.</jats:p></jats:sec>
収録刊行物
-
- British Journal of Pharmacology
-
British Journal of Pharmacology 176 (15), 2808-2824, 2019-06-24
Wiley
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1361131420393664896
-
- ISSN
- 14765381
- 00071188
-
- データソース種別
-
- Crossref
- KAKEN